Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Sunitinib is approved by both the FDA and EMA as a treatment for clear cell renal cell carcinoma (ccRCC), specifically for advanced or metastatic disease. The original FDA approval occurred in 2006 for advanced renal cell carcinoma, with clear cell histology being the most common subtype and the primary population in clinical trials supporting approval. Sunitinib has long been regarded as a standard first-line therapy for metastatic ccRCC. Recent therapies have introduced immunotherapy-based combinations, but sunitinib remains an approved and used agent for this indic…